Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CanariaBio Completes Enrollment of Phase 2 Oregovomab Trial for Ovarian Cancer
Details : Oregovomab, a murine monoclonal antibody against CA 125, in combination with paclitaxel and carboplatin, is being investigated in patients with newly diagnosed advanced epithelial ovarian cancer.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 10, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MAb-AR20.5
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MAb-AR20.5, an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed ubiquitously on pancreatic cancer cells.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : MAb-AR20.5
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oregovomab,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Successful enrollment completion of a Phase 2 study of Oregovomab, a murine monoclonal antibody against CA 125, in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurren...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Oregovomab,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MAb-B43.13 (oregovomab) is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 07, 2022
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Oregovomab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Korean Cancer Study Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : Oregovomab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Korean Cancer Study Group
Deal Size : Inapplicable
Deal Type : Inapplicable